Neutralizing Ljungan virus antibodies in children with newly diagnosed type 1 diabetes

Annika Lundstig, Sharia L McDonald, Marlena Maziarz, William C Weldon, Fariba Vaziri-Sani, Åke Lernmark, Anna-Lena Nilsson

Research output: Contribution to journalArticlepeer-review


Ljungan virus (LV), a Parechovirus of the Picornavirus family, first isolated from a bank vole at the Ljungan river in Sweden, has been implicated in the risk for autoimmune type 1 diabetes. An assay for neutralizing Ljungan virus antibodies (NLVA) was developed using the original 87-012 LV isolate. The goal was to determine NLVA titres in incident 0-18 years old newly diagnosed type 1 diabetes patients (n=67) and school children controls (n=292) from Jämtland county in Sweden. NLVA were found in 41 of 67 (61 %) patients compared to 127 of 292 (44 %) controls (P=0.009). In the type 1 diabetes patients, NLVA titres were associated with autoantibodies to glutamic acid decarboxylase (GADA) (P=0.023), but not to autoantibodies against insulin (IAA) or islet antigen-2 (IA-2A). The NLVA assay should prove useful for further investigations to determine levels of LV antibodies in patients and future studies to determine a possible role of LV in autoimmune type 1 diabetes.

Original languageEnglish
Article number1602
JournalThe Journal of general virology
Issue number5
Publication statusPublished - 2021

Subject classification (UKÄ)

  • Infectious Medicine
  • Endocrinology and Diabetes


Dive into the research topics of 'Neutralizing Ljungan virus antibodies in children with newly diagnosed type 1 diabetes'. Together they form a unique fingerprint.

Cite this